Their study demonstrated that combination therapy with anti-CTLA-4 and anti-PD-1 antibodies does not affect myeloid-driven vascular and systemic inflammation in melanoma patients and hyperlipidemic mice. This evidence concerns the gene PDCD1 and melanoma.